STRS Ohio’s Trevi Therapeutics TRVI Stock Holding History

STRS Ohio’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$302K	Buy	16,200 +3,400	+27%	+$49.4K	﹤0.01%	1402
2026 Q1	$153K	Sell	12,800 -10,900	-46%	-$122K	﹤0.01%	1604
2025 Q4	$297K	Sell	23,700 -8,600	-27%	-$99.4K	﹤0.01%	1338
2025 Q3	$296K	Buy	32,300 +8,300	+35%	+$62.2K	﹤0.01%	1342
2025 Q2	$131K	Buy	24,000 +15,800	+193%	+$98.3K	﹤0.01%	1788
2025 Q1	$51.6K	Hold	8,200	–	–	﹤0.01%	1767
2024 Q4	$33.8K	Hold	8,200	–	–	﹤0.01%	1771
2024 Q3	$27.4K	Hold	8,200	–	–	﹤0.01%	1873
2024 Q2	$24.4K	Hold	8,200	–	–	﹤0.01%	1881
2024 Q1	$28K	Sell	8,200 -500	-6%	-$1.12K	﹤0.01%	1827
2023 Q4	$11K	Hold	8,700	–	–	﹤0.01%	1873
2023 Q3	$18K	Hold	8,700	–	–	﹤0.01%	1880
2023 Q2	$20K	Buy	+8,700	New	+$21.9K	﹤0.01%	1886

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

STRS Ohio's TRVI Position: Q2 2026 in Review

STRS Ohio increased its Trevi Therapeutics (TRVI) stake by 27% in Q2 2026, buying an estimated $49.4K and bringing the position to 16,200 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #1402.

STRS Ohio first reported a position in TRVI in Q2 2023 and has held it in 13 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

STRS Ohio held 16,200 shares of Trevi Therapeutics worth $302K as of Q2 2026.
STRS Ohio bought 3,400 Trevi Therapeutics shares in Q2 2026, an estimated $49.4K.
Trevi Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1402 holding.
STRS Ohio first reported a position in Trevi Therapeutics in Q2 2023 and has held it in 13 quarters since.
219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.